Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (January 2022) - Gogas, Helen; Dummer, Reinhard; Ascierto, Paolo A.; Arance, Ana; Mandalà, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsová, Ivana; Gutzmer, Ralf; Chiarion Sileni, Vanna; Dutriaux, Caroline; et al.